Literature DB >> 18287318

Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Thomas Akerlund1, Ingela Persson, Magnus Unemo, Torbjörn Norén, Bo Svenungsson, Marlene Wullt, Lars G Burman.   

Abstract

Clostridium difficile PCR ribotype 027 comprised 0.2% of a collection of Swedish isolates in 1997-2001 (3 of 1,325 isolates). These isolates had lower moxifloxacin MICs than the epidemic type 027 isolates, but they had the same tcdC sequence and toxin yield. Type 027 produced 3- to 13-fold more toxin than did major Swedish types. One epidemic strain (027/NAP1a) sporulated more than did other type 027 isolates, a feature that should contribute to its survival and spread.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18287318      PMCID： PMC2292905          DOI： 10.1128/JCM.01964-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  37 in total

1.  Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec.

Authors:  Jacques Pépin; Louis Valiquette; Benoit Cossette
Journal:  CMAJ       Date:  2005-09-22       Impact factor: 8.262

2.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors:  Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

3.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

4.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

5.  Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids.

Authors:  Sture Karlsson; Lars G Burman; Thomas Åkerlund
Journal:  Microbiology       Date:  1999-07       Impact factor: 2.777

6.  Genotyping of outbreak-related and sporadic isolates of Clostridium difficile belonging to serogroup C.

Authors:  P van Dijck; V Avesani; M Delmée
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

Review 7.  Clostridium difficile-associated diarrhea and colitis.

Authors:  D N Gerding; S Johnson; L R Peterson; M E Mulligan; J Silva
Journal:  Infect Control Hosp Epidemiol       Date:  1995-08       Impact factor: 3.254

8.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

9.  Comparison of AP-PCR typing and PCR-ribotyping for estimation of nosocomial transmission of Clostridium difficile.

Authors:  M Wullt; L G Burman; M H Laurell; T Akerlund
Journal:  J Hosp Infect       Date:  2003-10       Impact factor: 3.926

10.  Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.

Authors:  Robert Gaynes; David Rimland; Edna Killum; H Ken Lowery; Theodore M Johnson; George Killgore; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2004-02-11       Impact factor: 9.079
View more
  89 in total

1.  Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.

Authors:  Stéphanie Sirard; Louis Valiquette; Louis-Charles Fortier
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

2.  Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.

Authors:  Michael John Aldape; Dustin Delaney Heeney; Amy Evelyn Bryant; Dennis Leroy Stevens
Journal:  J Antimicrob Chemother       Date:  2014-08-23       Impact factor: 5.790

Review 3.  Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty?

Authors:  Fred C Tenover; Ellen Jo Baron; Lance R Peterson; David H Persing
Journal:  J Mol Diagn       Date:  2011-08-18       Impact factor: 5.568

4.  Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples.

Authors:  Paul D Stamper; Romina Alcabasa; Deborah Aird; Wisal Babiker; Jennifer Wehrlin; Ijeoma Ikpeama; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

Review 5.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

6.  Premarket evaluations of the IMDx C. difficile for Abbott m2000 Assay and the BD Max Cdiff Assay.

Authors:  K A Stellrecht; A A Espino; V P Maceira; S M Nattanmai; S A Butt; D Wroblewski; G E Hannett; K A Musser
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

Review 7.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

8.  Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use.

Authors:  Judith Maria Wenisch; Susanne Equiluz-Bruck; Marta Fudel; Ingun Reiter; Andrea Schmid; Erna Singer; Andreas Chott
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

9.  Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production.

Authors:  Sarah Underwood; Shuang Guan; Vinod Vijayasubhash; Simon D Baines; Luke Graham; Richard J Lewis; Mark H Wilcox; Keith Stephenson
Journal:  J Bacteriol       Date:  2009-09-25       Impact factor: 3.490

Review 10.  Diagnosis and treatment of acute or persistent diarrhea.

Authors:  Sean W Pawlowski; Cirle Alcantara Warren; Richard Guerrant
Journal:  Gastroenterology       Date:  2009-05-07       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.